[1]高延秋△,张华,刘敏,等.血必净注射液治疗重症肺炎的临床疗效和安全性评价*[J].郑州大学学报(医学版),2014,(06):837.
 GAO Yanqiu,ZHANG Hua,LIU Min,et al.Clinical efficacy and safety observation of Xuebijing injection in patients with severe pneumonia[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2014,(06):837.
点击复制

血必净注射液治疗重症肺炎的临床疗效和安全性评价*
分享到:

《郑州大学学报(医学版)》[ISSN:1671-6825/CN:41-1340/R]

卷:
期数:
2014年06期
页码:
837
栏目:
应用研究
出版日期:
2014-11-20

文章信息/Info

Title:
Clinical efficacy and safety observation of Xuebijing injection in patients with severe pneumonia
作者:
高延秋△张华刘敏周丽娟孙广信任英杰
郑州大学附属郑州中心医院呼吸重症医学科 郑州 450007
Author(s):
GAO YanqiuZHANG HuaLIU MinZHOU LijuanSUN GuangxinREN Yingjie
Respiratory Intensive Care Unit,the Affiliated Zhengzhou Central Hospital, Zhengzhou University,Zhengzhou 450007
关键词:
血必净注射液重症肺炎临床疗效安全性
Keywords:
Xuebijing injectionsevere pneumoniaclinical efficacysafety
分类号:
R563.1
摘要:
目的:观察血必净注射液治疗重症肺炎的临床疗效和安全性。方法:将126例重症肺炎患者分为常规组(63例)和治疗组(63例),常规组给予常规抗感染、祛痰、机械通气、对症支持治疗,治疗组在此基础上加用血必净注射液静脉滴注,14 d为一个疗程。比较2组患者临床疗效和安全性。结果:治疗组总有效率(87.30%)高于常规组(66.67%)(χ2=7.570,P=0.006)。治疗组较常规组缩短了机械通气时间、抗生素使用时间和住院时间(t=7.183、6.102、7.616,P均<0.001),降低了60 d病死率(7.94% vs 20.63%,χ2=4.148,P=0.036)。2组患者均未发生与药物相关的严重不良反应。结论:在常规西药治疗的基础上加用血必净注射液治疗重症肺炎,具有一定的临床应用价值。
Abstract:
Aim: To observe the clinical efficacy and safety of Xuebijing injection in patients with severe pneumonia. Methods: A total of 126 patients with severe pneumonia were divided into routine group(n=63)and treatment group(n=63). Patients in the routine group were in routine therapy. Treatment of routine therapy combined with Xuebijing injection was applied in the treatment group. The clinical efficacy in the two groups were observed. Results: The effective rate was higher in treatment group than that of the routine group(87.30% vs 66.67%,χ2=7.570,P=0.006). The mechanical ventilation time,antibiotic using time, and hospital stay shortened in treatment group(t=7.183,6.102,7.616,P<0.001). The fatality rate at 60th of treatment group was lower compared with that of routine group(7.94% vs 20.63%,χ2=4.148,P=0.036). There were no obvious adverse reaction in two groups. Conclusion: Treatment of routine therapy combined with Xuebijing injection for severe pneumonia has certain clinical application value.

参考文献/References:

[1]Sibila O,Meduri GU,Mortensen EM,et al.Improving the 2007 Infectious Disease Society of America/American Thoracic Society severe communityacquired pneumonia criteria to predict intensive care unit admission[J].J Crit Care,2013,28(3):284 [2]Milbrandt EB,Reade MC,Lee M,et al.Prevalence and significance of coagulation abnormalities in communityacquired pneumonia[J].Mol Med,2009,15(11/12):438 [3]滕寅,肖家荣,林鹏,等.血必净注射液对重症肺炎患者细胞免疫及炎症因子的影响[J].中国实验方剂学杂志,2012,18(17):295 [4]焦丽娜,姚咏明,寿松涛.血必净注射液对脓毒症大鼠肝组织凝溶胶蛋白及炎症因子的影响[J].解放军医学杂志,2011,36(1):14 [5]Mandell LA,Wunderink RG,Anzueto A,et al.Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of communityacquired pneumonia in adults[J].Clin Infect Dis,2007,44(Suppl 2):S27 [6]Qi F,Liang ZX,She DY,et al.A clinical study on the effects and mechanism of xuebijing injection in severe pneumonia patients[J].J Tradit Chin Med,2011,31(1):46 [7]方凯,王晓玲.血必净注射液对多器官功能障碍综合征的临床作用研究[J].中国中西医结合杂志,2013,33(2):205 [8]Mitamura M,Komiya K,Watanabe H,et al.Mechanical ventilation for very elderly patients with severe pneumonia[J].J Palliat Med,2014,17(4):383 [9]王立强,陈志诚,王轩,等.血必净注射液治疗重症肺炎的疗效观察[J].青岛医药卫生,2014,46(3):187 [10]孟泳,刘晓光.中药离子导入配合药物治疗成人支气管肺炎疗效观察[J].郑州大学学报:医学版,2014,49(3):417 [11]马世堂.血必净防治脓毒症作用机制的研究[D].北京:中国协和医科大学,2010. [12]Sun J,Xue Q,Guo L,et al.Xuebijing protects against lipopolysaccharideinduced lung injury in rabbits[J].Exp Lung Res,2010,36(4):211

相似文献/References:

[1]乔俊英,王秀芳,栾斌.婴幼儿重症肺炎181例临床分析[J].郑州大学学报(医学版),2009,(06):1293.
[2]高延秋△,张华,刘敏,等.重症肺炎患者外周血IL-6和IL-18水平的检测[J].郑州大学学报(医学版),2015,(04):555.
 GAO Yanqiu,ZHANG Hua,LIU Min,et al.Determination of peripheral blood IL6 and IL18 in patients with severe pneumonia[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2015,(06):555.

备注/Memo

备注/Memo:
*郑州市中原区科技攻关计划项目中原科[2013]23号;△女,1972年11月生,硕士,副主任医师,研究方向:呼吸与危重症,Email:drgaoyanqiu@126.com
更新日期/Last Update: 2014-11-26